GSK, researchers still probing Pandemrix links to narcolepsy; CHMP wants more justification for Arena's Belviq;

@FiercePharma: ADHD diagnoses up 24% over past 10 years; study author cites "better diagnosis" and possible "upward trend." More | Follow @FiercePharma

 @AlisonBFierce: Vanderbilt University has emerged as a leading institution for central nervous system drug research and discovery. Editor's Corner | Follow @AlisonBFierce

@EricPFierce: Plant problems stymie Impax NDA for Parkinson drug, FDA says. Article | Follow @EricPFierce

> GlaxoSmithKline ($GSK) and independent researchers continue to probe a possible link between the pandemic flu shot Pandemrix and hundreds of cases of narcolepsy. Report

> European regulators asked Arena Pharmaceuticals ($ARNA) to "further justify" the safety and efficacy of its weight-loss drug Belviq, which awaits a recommendation from the Committee for Medicinal Products for Human Use. Report

> GlaxoSmithKline is cutting the calories and sugar in its energy and nutrition drinks Lucozade and Ribena, as part of a government plan to fight obesity. Report

> Italy's Recordati wrapped up its $100 million buyout of a portfolio of Lundbeck's U.S. product rights, including Panhematin and NeoProfen. Release | Report

> The number of children diagnosed with Attention Deficit Hyperactivity Disorder rose by 24% over the past decade, partly because of improved diagnosis, a JAMA Pediatrics study found. Report

Medical Device News

 @FierceMedDev: J&J device revenue jumped 6.4% in 2012 thanks to Synthes buy. Report | Follow @FierceMedDev

 @DamianFierce: If $LIFE is indeed for sale, that's not stopping it from pursuing more M&A of its own. More | Follow @DamianFierce

> Welch Allyn snags FDA clearance for iPhone-friendly eye scope. Article

> Invacare closes $150M unit sale as it reels from FDA fallout. Story

Biotech News

 @FierceBiotech: Novo Nordisk nabs European OK on blockbuster diabetes drug hopeful. News | Follow @FierceBiotech

@JohnCFierce: As CRL letters go, Impax would seem to have a low hurdle ahead on its sustained release Parkinson's drug. More | Follow @JohnCFierce

@RyanMFierce: Software outfit tackles multi-billion dollar bugaboo in clinical trials. Article | Follow @RyanMFierce

> New $80M venture fund to back startups entering 'valley of death.' Story

> Biotech vet Astley-Sparke takes U.S. lead for pioneering gene therapy player. Article

Biotech IT News

> New chief named for Perceptive Informatics. Story

> U.K. regulator finds social media groove…finally. Item

> Software outfit tackles multi-billion dollar bugaboo in clinical trials. Article

> Elsevier rumored as potential buyer of open science startup. News

CRO News

> Is GlaxoSmithKline stretching its contractors too thin? Story

> Covance teams with U.K.'s NHS Trust on Phase I trials. Report

> Clinipace rejiggers eClinical platform. Article

> Quintiles lands pathology accreditation for Indian lab. News

Pharma Manufacturing News

> BASF lands Pronova making it a top omega-3 maker. Report

> Pfizer to develop laser cleaning verification system. Item

> Cargo theft down in year of key arrests. News

> Plant problems stymie Impax NDA, FDA says. Article

Biotech Research News

> Calcium receptor could stop sleeping sickness in its tracks. Item

> Oral breast cancer vaccine could prevent recurrence. Article

> A great leap forward: Microdystrophin gene therapy success in dogs. Report

> Glowing mice could blaze way for detecting, tracking cancer growth. News

And Finally... Doctors need better training in talking about new drugs to their patients, a study found. Report


Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.